Please rotate the screen for the best
viewing experience. Thank you.
This website was designed with newer technology in mind. Please update your current browser or switch to a recently updated browser. Thank you.
Based on our Organs-on-Chips technology, we have created a new living system that emulates human biology – for understanding how different diseases, medicines, chemicals and foods affect human health. Our team’s work is driven by the following three guiding principles:
James Coon is the CEO of Emulate. He is an accomplished entrepreneur who brings over 20 years of experience in founding life sciences companies, developing new products and executing commercialization strategies.
James Coon is the Chief Executive Officer of Emulate and has been in the biotechnology and pharmaceutical industry for over 20 years. Coon has most recently served as Entrepreneur in Residence at the Wyss Institute for Biologically Inspired Engineering at Harvard University, providing researchers with insights on commercialization and product development, target markets, and fundraising strategies in both Nanotherapeutic and Organs-on-Chips technologies.
Coon has served as a co-founder, executive management, and strategic partner for numerous healthcare and biotech startup companies, including roles as President of RxGen, President and CEO of BCS, Inc., President and CEO of HepatoTech, Inc., Executive Vice-President of CellzDirect (acquired by Invitrogen-Life Technologies), and the Senior Director of Business Development for RTI International.
Earlier in his career, Coon held a range of management positions at Fisons Pharmaceutical, Astra Arcus, AstraZeneca, and GlaxoSmithKline. He received his undergraduate degree in Biochemistry from the Rochester Institute of Technology, and completed his graduate work in liver cell biology at the University of North Carolina at Chapel Hill School of Medicine.
Geraldine A. Hamilton, Ph.D. serves as the President and CSO of Emulate. She is a recognized cell biologist and toxicologist focused on developing and applying innovative cell-based technologies.
Geraldine A. Hamilton is the President and Chief Scientific Officer of Emulate. Prior to joining Emulate’s founding team, she served as Lead Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss Institute, Hamilton lead the Organs-on-Chips program and managed the multidisciplinary team responsible for developing, translating and commercializing the Organs-on-Chips technology.
Hamilton’s career spans industry, academia and the start-up world. Prior to her tenure at Harvard University, Hamilton spent more than 11 years in the pharmaceutical industry in leadership roles managing drug discovery teams. Her research achievements helped advance the development and application of human relevant in vitro models for drug discovery. Hamilton was a founding scientist and VP of Scientific Operations for CellzDirect, a start-up biotech company that specialized in providing cell products to the pharmaceutical industry for safety testing. Hamilton was responsible for the successful translation of CellzDirect’s technology from academia to broad use and acceptance across the industry.
Hamilton received her Ph.D. in cell biology/toxicology from the University of Hertfordshire (England) in conjunction with GlaxoSmithkline, followed by a post-doctoral research fellowship at the University of North Carolina. She has authored more than 40 publications and numerous patents.
Donald Ingber is a pioneer in the field of Organs-on-Chips. The technology emerged from his leadership as the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Donald Ingber is the Scientific Founder and Chair of the Scientific Advisory Board for Emulate. In addition to his Founding Director role at the Wyss Institute, he is the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences.
Dr. Ingber is recognized as a pioneer of the emerging field of biologically inspired engineering, and oversees efforts at the Wyss Institute that strive to identify the mechanisms that living organisms use to self-assemble, and to apply these principles to develop advanced materials and devices for healthcare and the environment. He led the Organs-on-Chips development program at the Wyss Institute that resulted in the creation of Emulate’s automated bioemulation platform. Dr. Ingber has also made major contributions to mechanobiology, tissue engineering, tumor angiogenesis, systems biology, and nanobiotechnology.
Dr. Ingber has authored more than 375 publications and 85 patents, and has received numerous honors, including the NC3Rs Annual Award from the National Centre for the Replacement, Refinement, and Reduction of Animals in Research, and both the Leading Edge Award and Honorary Membership from the Society of Toxicology. He is also a member of both the American Institute for Medical and Biological Engineering and the Institute of Medicine of the National Academies. Ingber received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Daniel Levner, Ph.D. is Emulate’s Chief Technology Officer. He is a recognized engineer and biotechnologist with extensive experience in the commercialization of innovative research.
Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a as a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulating innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture.
Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.
Greg Williams is Vice President and General Counsel for Emulate. He has a wealth of experience with high-growth biotechnology companies and in intellectual property law.
Greg Williams is Vice President and General Counsel for Emulate, bringing decades of experience in legal practice in the life sciences sector.
Williams is a former partner in the Intellectual Property Practice Group of Pepper Hamilton LLP, with a focus on intellectual property acquisition and management, including IP asset strategy, contracts, licensing portfolio development and management, patent, trademark, technology transfer and strategic alliance negotiation/restructuring. Previously, Williams served as general counsel and a senior member of the global business development team for New England Biolabs, where he was responsible for business development, organizational management and non-IP affairs oversight (employment, compliance, property, etc.) and strategic counseling.
Williams received his undergraduate degree in Chemistry and Biology from McGill University in Montreal, Canada, and his first law degree from McGill University and a Masters of Law (LL.M.) with specialization in intellectual property and anti-trust law from the University of Pennsylvania Law School.
Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our Human Emulation System sets a new standard for recreating true-to-life human biology and is being used to advance product innovation, design, and safety across a range of applications including drug development, agriculture, cosmetics, food, and chemical-based consumer products.
Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems.
Emulate continues to develop a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs. Emulate is also working with clinical partners to produce Organ-Chips personalized with an individual patient’s stem cells, for applications in precision medicine and personalized health.
Private investor, Hansjörg WyssRead More
Cedars-Sinai Medical CenterRead More
The OS FundRead More
Atel Ventures, Inc.Read More
Venture capital firm, NanoDimensionRead More
Learn about where Emulate is being talked about in the media.read more
HQ: 27 Drydock Ave, Boston, MA 02210